Company logo

XGN - Exagen Inc.

NASDAQ -> Healthcare -> Diagnostics & Research
Vista, United States
Type: Equity

XGN price evolution
XGN
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $24.48 $27.27 $36.49
Short term investments
Net receivables $9.39 $11.7 $10.9 $6.55
Inventory
Total current assets $35.56 $40.79 $42.4 $47.84
Long term investments
Property, plant & equipment $7.49 $8 $7.85 $8.49
Goodwill & intangible assets
Total noncurrent assets $8.51 $8.41 $9.1
Total investments
Total assets $43.6 $49.31 $50.81 $56.94
Current liabilities
Accounts payable $1.1 $2.33 $1.47 $3.13
Deferred revenue
Short long term debt $1.46 $1.27 $1.24
Total current liabilities $8.78 $9.45 $8.78 $11.9
Long term debt $19.82 $22.06 $21.77 $21.99
Total noncurrent liabilities $22.28 $22.03 $22.35
Total debt $23.52 $23.04 $23.23
Total liabilities $30.74 $31.72 $30.82 $34.25
Shareholders' equity
Retained earnings -$290.57 -$285.54 -$282.58 -$279.22
Other shareholder equity
Total shareholder equity $17.59 $19.99 $22.69
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $36.49 $62.39 $99.44 $57.45
Short term investments
Net receivables $6.55 $6.08 $9.65 $8.91
Inventory $1.2
Total current assets $47.84 $72.61 $112.73 $70.52
Long term investments
Property, plant & equipment $8.49 $13.08 $4.77 $2.1
Goodwill & intangible assets $5.51 $5.51
Total noncurrent assets $9.1 $13.61 $10.71 $7.86
Total investments
Total assets $56.94 $86.22 $123.44 $78.38
Current liabilities
Accounts payable $3.13 $3.05 $2.49 $3.01
Deferred revenue
Short long term debt $1.24 $1.23
Total current liabilities $11.9 $9.62 $9.32 $8.77
Long term debt $21.99 $29.63 $27.48 $26.66
Total noncurrent liabilities $22.35 $34.14 $29.19 $27.77
Total debt $23.23 $34.5 $27.48 $26.66
Total liabilities $34.25 $43.76 $38.51 $36.54
Shareholders' equity
Retained earnings -$279.22 -$255.53 -$208.14 -$181.29
Other shareholder equity
Total shareholder equity $22.69 $42.46 $84.94 $41.84
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue $12.51 $15.06 $14.41 $13.77
Cost of revenue $6.01 $5.82 $5.62
Gross Profit $6.98 $9.06 $8.6 $8.14
Operating activities
Research & development $1.18 $1.06 $1.08
Selling, general & administrative $10.46 $10.54 $12.22
Total operating expenses $11.64 $11.64 $11.6 $13.29
Operating income -$2.59 -$3 -$5.15
Income from continuing operations
EBIT -$2.41 -$2.81 -$4.97
Income tax expense $0.03
Interest expense -$0.56 $0.56 $0.55 $0.57
Net income
Net income -$5.03 -$2.97 -$3.36 -$5.57
Income (for common shares) -$2.97 -$3.36 -$5.57
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $52.55 $45.56 $48.3 $41.98
Cost of revenue $23.09 $24.21 $20.59 $16.56
Gross Profit $29.46 $21.35 $27.71 $25.42
Operating activities
Research & development $4.87 $9.88 $7.24 $3.57
Selling, general & administrative $47.43 $52.02 $44.54 $37.03
Total operating expenses $52.29 $67.4 $51.78 $40.6
Operating income -$22.84 -$46.05 -$24.07 -$15.19
Income from continuing operations
EBIT -$21.32 -$45.22 -$24.05 -$14.2
Income tax expense $0.03 -$0.28 $0.17 -$0.08
Interest expense $2.33 $2.45 $2.63 $2.56
Net income
Net income -$23.69 -$47.39 -$26.85 -$16.69
Income (for common shares) -$23.69 -$47.39 -$26.85 -$16.69
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$2.97 -$3.36 -$5.57
Operating activities
Depreciation $0.65 $0.67 $0.73
Business acquisitions & disposals
Stock-based compensation $0.56 $0.55 $0.76
Total cash flows from operations -$2.43 -$9.04 $8.35
Investing activities
Capital expenditures -$0.14 -$0.09 -$0.08
Investments
Total cash flows from investing -$0.37 -$0.14 -$0.09 -$0.08
Financing activities
Dividends paid
Sale and purchase of stock $0.1
Net borrowings -$0.23 -$0.2 -$0.22
Total cash flows from financing -$0.45 -$0.23 -$0.1 -$0.22
Effect of exchange rate
Change in cash and equivalents -$14.46 -$2.79 -$9.23 $8.04
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$23.69 -$47.39 -$26.85 -$16.69
Operating activities
Depreciation $3.11 $2.52 $0.95 $0.55
Business acquisitions & disposals
Stock-based compensation $3.62 $4.7 $4.73 $2.69
Total cash flows from operations -$14.46 -$32.14 -$20.27 -$14.08
Investing activities
Capital expenditures -$0.8 -$4.32 -$2.37 -$0.46
Investments
Total cash flows from investing -$0.8 -$4.32 -$2.42 -$0.46
Financing activities
Dividends paid
Sale and purchase of stock $0.31 $0.45 $65.25 $0.16
Net borrowings -$10.94 -$0.7 -$0.53 -$0.25
Total cash flows from financing -$10.63 -$0.49 $64.68 -$0.1
Effect of exchange rate
Change in cash and equivalents -$25.9 -$36.95 $41.99 -$14.64
News
Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?
Zacks · via Yahoo Finance 6 Feb 2025
Exagen Gains 28%, Insider Trades Reap Benefit
Simply Wall St. · via Yahoo Finance 20 Jan 2025
Data Storage And 2 Other US Penny Stocks To Watch
Simply Wall St. · via Yahoo Finance 11 Dec 2024
Exagen Inc (XGN) Q3 2024 Earnings Report Preview: What To Expect
GuruFocus.com · via Yahoo Finance 11 Nov 2024
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Annual Report
Simply Wall St. via Yahoo Finance 21 Mar 2024
Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance 20 Mar 2024
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance 19 Mar 2024
Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates
Zacks via Yahoo Finance 29 Feb 2024
Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock
Zacks via Yahoo Finance 7 Feb 2024
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance 8 Aug 2023
Fundamentals
Market cap $70.61M
Enterprise value N/A
Shares outstanding 17.52M
Revenue $55.75M
EBITDA N/A
EBIT N/A
Net Income -$16.93M
Revenue Q/Q -6.78%
Revenue Y/Y 8.00%
P/E ratio -4.17
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 1.27
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$0.97
ROA -33.74%
ROE N/A
Debt/Equity 1.51
Net debt/EBITDA N/A
Current ratio 4.05
Quick ratio N/A